

- Other
- Alimta™ will be given in Carboplatin-based regimen in combination with bevacizumab (Avastin®)
 - Performance status (PS) 0-1
 - No history of hemoptysis
 - Other
- Alimta® will be given as single agent
 - Performance status (PS) 2
 - Elderly individual
 - Other
- Individual diagnosed with recurrent disease
 - Alimta® will be given in combination with Cisplatin
 - Performance status (PS) 0-2
 - Elderly individual
 - Other
 - Alimta® will be given in Cisplatin-based regimen in combination with bevacizumab (Avastin®)
 - Performance status (PS) 0-1
 - No history of hemoptysis
 - Other
 - Alimta® will be given in combination with Carboplatin
 - Performance status (PS) 0-2
 - Elderly individual
 - Other
 - Alimta™ will be given in Carboplatin-based regimen in combination with bevacizumab (Avastin®)
 - Performance status (PS) 0-1
 - No history of hemoptysis
 - Other
 - Alimta® will be given as single agent
 - Performance status (PS) 2
 - Elderly individual
 - Other
- Alimta® will be given as single agent after prior chemotherapy for tumors of nonsquamous cell histology
 - Individual diagnosed with locally advanced disease
 - Individual diagnosed with metastatic disease
 - Other
- Alimta® will be given as adjuvant chemotherapy in combination with cisplatin (**NOTE: does not apply for T2a and T2b, N0 with negative margins**)
 - Stage IB, IIA and IIB (T3, N0; T2b, N1)
 - T1-2, T3 (7or more cm), N2, M0 with stable disease or local progression
 - T3 invasion or T4 extension, N0-1 tumors in the chest wall, proximal airway, or mediastinum if not given as initial treatment
 - Resectable or marginally resectable superior sulcus tumors (T3 invasion, T4 extension, N0-1)
 - Margin-negative separate pulmonary nodule(s)
 - Other
- Alimta® will be given as switch maintenance for tumors of nonsquamous cell histology
 - Individual diagnosed with recurrent disease
 - Individual diagnosed with metastatic disease
 - Alimta® will be given as single agent
 - Performance (PS) 0-2 in individual who achieves tumor response or stable disease following first-line chemotherapy
 - Other
- Alimta® will be given as maintenance therapy for tumors of nonsquamous cell histology
 - Individual diagnosed with locally advanced disease
 - Individual diagnosed with metastatic disease
 - Individual's disease has not progressed after four cycles of platinum-based first-line chemotherapy
 - Other:
- Other:

2. Mesothelioma

- Individual has been diagnosed with malignant pleural mesothelioma
 - To be used in combination with cisplatin for the treatment of the following: **please check all that apply**
 - Disease is unresectable
 - Not a candidate for curative surgery
 - Induction therapy for medically operable clinical stage II-III disease
 - Other:
 - To be used in combination with cisplatin or carboplatin for the treatment of the following: **please check all that apply**
 - Adjuvant treatment for clinical stage II-III disease
 - First-line treatment for unresectable or medically inoperable clinical stage I-III disease
 - First-line treatment for clinical stage IV disease

- First-line treatment for tumors of sarcomatoid histology
- Second-line treatment if Alimta® was not used as first line treatment
- Other:

Other:

3. Bladder Cancer (including upper GU tract tumors)

- Individual has been diagnosed with bladder cancer
 - This will be used for metastatic disease
 - This will be used as second-line therapy
 - This will be used as a single agent
 - Other:

4. Thymic malignancy/Thymoma

- Individual has been diagnosed with thymic malignancy or thymoma
 - This will be used for locally advanced, unresectable disease
 - This will be used following radiation therapy
 - This will be used as second line therapy
 - This will be used as a single agent
 - Other:

5. Ovarian Cancer

- Individual has been diagnosed with ovarian cancer (epithelial ovarian cancer: fallopian tube cancer: primary peritoneal cancer)
 - This is to be used as single agent recurrence therapy if platinum resistant
 - To be used for progressive, stable, or persistent disease on primary chemotherapy
 - To be used for relapse after complete remission following primary chemotherapy
 - To be used for Stage II-IV disease showing partial response to primary treatment
 - Other:

Other:

6. Other Use(s) (Please submit all supporting documents including labs, progress notes, imaging, etc., for review.)

This request is being submitted:

- Pre-Claim
- Post-Claim. If checked, please attach the claim or indicate the claim number _____

I attest the information provided is true and accurate to the best of my knowledge. I understand that the health plan or its designee may perform a routine audit and request the medical documentation to verify the accuracy of the information reported on this form.

Name & Title of Provider or Provider Representative Completing Form
& attestation (Please Print)*

/ /
Date

***The attestation fields must be completed by a provider or provider representative in order for the tool to be accepted**

Anthem UM Services, Inc., a separate company, is the licensed utilization review agent that performs utilization management services on behalf of your health benefit plan or the administrator of your health benefit plan